In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD)  to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into  Ainos’ latest strategic partnerships with Topco and NEXCOM, its expanding IP moat with seven new patents, and  outlines the roadmap for 2026—commercial scale-up, industrial deployments and expansion plans beyond Asia.

Hear about the latest dynamic developments in the therapeutic psychedelics sector in our WTR Healthcare Happenings Flashcast. Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer at WTR, and Robert Sassoon, WTR's Senior Healthcare Analyst, discuss the  October's fundraising activity surge; what has contributed to renewed investor confidence; comparisons with the hype-driven cycle of 2021; impact on valuations in the sector; and sustainability of the positive trend going into 2026.  

In this episode of WTR Healthcare Happenings, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon.

The clinical-stage, UK-listed company (LSE: SVNS) focuses on developing novel medicines for high-burden CNS disorders, with its current focus primarily on Alcohol Use Disorder (AUD). Our discussion delves into  Solvonis' lead clinical programs, SVN-001 and SVN-002, that aim to address this major societal problem. Tennyson highlights anticipated upcoming milestones and outlines Solvonis' capital-efficient business model and financial strategy to advance its AUD programs to commercialization. 

In this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (TSXV: NRX | OTCQB: NRXBF), and Yoram Drucker, Founder, VP of Business Development, and Active Chairman, join host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, along with WTR Senior Equity Research Analyst Robert Sassoon.

The conversation explores NurExone’s groundbreaking exosome-based ExoTherapy platform and its lead candidate ExoPTEN, designed to regenerate damaged neurons following spinal cord and optic nerve injuries—two massive unmet medical markets. Shaltiel and Drucker discuss the company’s remarkable preclinical data showing functional recovery in up to 100% of animal models, the mechanism of action behind their siRNA-loaded exosomes, and why their cell-free, off-the-shelf therapy may become a game-changer for central nervous system repair.

They also highlight NurExone’s U.S. manufacturing subsidiary, ExoTop, expected to begin generating revenue in 2026, and share updates on regulatory milestones, cash position, and plans to uplist to a U.S. national exchange.

In this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Amit Kumar, PhD, CEO of Anixa Biosciences (NASDAQ: ANIX) to discuss t-cells and Anixa's two clinical developments, one involving the modification of CAR-T technology to overcome the challenges of treating solid tumors, specifically ovarian cancer, and the other, an innovative breast cancer vaccine that trains antigen-specific t-cells  to recognize and attack breast cancer cells, especially those from triple-negative breast cancer, the most aggressive form of breast cancer.  Kumar also talks about the company's robust balance sheet and financial strategy to advance Anixa's clinical developments to commercialization.  

We welcome back Veru's CEO Mitch Steiner to our latest WTR Healthcare Happenings podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosarm's Phase 2b data, and explains  Veru's obesity drug development strategy in the wake of its recent positive interactions with the FDA.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Marvin Slosman, CEO of InspireMD (NASDAQ: NSPR), to discuss how the company is transforming carotid artery disease treatment with its groundbreaking CGuard® Prime Carotid Stent System. The conversation covers FDA approval, clinical data, market adoption, competitive positioning, and InspireMD’s long-term growth strategy.

In this episode of the WTR Healthcare Happenings Podcast, Water Tower Research’s Tim Gerdeman and Robert Sassoon sit down with Charles Nader, CEO of Doc.com, to discuss the company’s mission to provide free basic telehealth services worldwide. The conversation covers Doc.com’s innovative use of AI and blockchain, strategic partnerships, competitive differentiation, and plans for scaling telemedicine and pharmacy services globally.

In this special Flashcast edition of the WTR Small-Cap Spotlight Podcast, host Tim Gerdeman sits down with Robert Sassoon, Senior Research Analyst at Water Tower Research, to discuss the recent wave of deal activity in the psychedelics sector.

Robert breaks down major transactions, including why the AbbVie/Gilgamesh deal marks a potential turning point for the industry, and what these developments could mean for sector valuations going forward.

Whether you’re an investor tracking emerging growth sectors or just curious about the rapidly evolving psychedelics market, this quick-hit episode provides the essential insights you need to stay ahead.